DREAMM-9 Final Analysis: Blenrep + VRd Shows Lasting Benefit in Newly Diagnosed Myeloma | EHA 2026

The final analysis of the DREAMM-9 study, presented at EHA 2026, provides important insights into the use of belantamab mafodotin (Blenrep) in newly diagnosed multiple myeloma patients who are not eligible for stem cell transplant. In this video, we review the latest results from DREAMM-9, a phase 3 clinical trial evaluating Blenrep in combination with VRd (bortezomib, lenalidomide, and dexamethasone) as frontline therapy. Learn how the addition of this BCMA-targeted antibody-drug conjugate impacted response rates, progression-free survival, MRD negativity, and overall treatment outcomes. #MultipleMyeloma #EHA2026 #DREAMM9 #Blenrep #BelantamabMafodotin #BCMA #MyelomaResearch #MyelomaTreatment #Hematology #CancerResearch If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/6286... For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer! Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_so... Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.